Selektivní modulátor receptoru androgenu (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "Selektivní modulátor receptoru androgenu" in Czech language version.

refsWebsite
Global rank Czech rank
2nd place
4th place
4th place
8th place
low place
low place
low place
low place
1st place
1st place
low place
low place
low place
low place
1,100th place
2,171st place
7th place
43rd place
447th place
753rd place

asco.org

  • M.S. Steiner. Effect of GTx-024, a selective androgen receptor modulator (SARM), on stair climb and quality of life (QOL) in patients with cancer cachexia. J Clin Oncol. June 2010. Dostupné v archivu pořízeném dne 2012-08-25.  Archivovaná kopie. www.asco.org [online]. [cit. 2019-01-22]. Dostupné v archivu pořízeném z originálu dne 2012-08-25. 

doi.org

  • Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. Journal of Medicinal Chemistry. June 2009, s. 3597–617. doi:10.1021/jm900280m. PMID 19432422. 
  • Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT. Pharmacodynamics of selective androgen receptor modulators. The Journal of Pharmacology and Experimental Therapeutics. March 2003, s. 1334–40. doi:10.1124/jpet.102.040840. PMID 12604714. 
  • Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biological & Pharmaceutical Bulletin. November 2003, s. 1563–9. doi:10.1248/bpb.26.1563. PMID 14600402. 
  • Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology. January 2007, s. 4–12. doi:10.1210/en.2006-0843. PMID 17008401. 
  • Manfredi MC, Bi Y, Nirschl AA, Sutton JC, Seethala R, Golla R, Beehler BC, Sleph PG, Grover GJ, Ostrowski J, Hamann LG. Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators. Bioorganic & Medicinal Chemistry Letters. August 2007, s. 4487–90. doi:10.1016/j.bmcl.2007.06.007. PMID 17574413. 
  • Zhang X, Li X, Allan GF, Sbriscia T, Linton O, Lundeen SG, Sui Z. Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators. Journal of Medicinal Chemistry. August 2007, s. 3857–69. doi:10.1021/jm0613976. PMID 17636947. 
  • Long YO, Higuchi RI, Caferro TR, Lau TL, Wu M, Cummings ML, Martinborough EA, Marschke KB, Chang WY, López FJ, Karanewsky DS, Zhi L. Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity. Bioorganic & Medicinal Chemistry Letters. May 2008, s. 2967–71. doi:10.1016/j.bmcl.2008.03.062. PMID 18400499. 
  • Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. The Journal of Clinical Endocrinology and Metabolism. October 1999, s. 3459–62. doi:10.1210/jc.84.10.3459. PMID 10522980. 
  • Piu F, Gardell LR, Son T, Schlienger N, Lund BW, Schiffer HH, Vanover KE, Davis RE, Olsson R, Bradley SR. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. The Journal of Steroid Biochemistry and Molecular Biology. March 2008, s. 129–37. doi:10.1016/j.jsbmb.2007.11.001. PMID 18164613. 
  • Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. The Journal of Pharmacology and Experimental Therapeutics. February 2009, s. 663–70. doi:10.1124/jpet.108.146811. PMID 19017848. 
  • Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. January 2009, s. 385–95. doi:10.1210/en.2008-0674. PMID 18772237. 
  • Miller CP, Shomali M, Lyttle CR, O'Dea LS, Herendeen H, Gallacher K, Paquin D, Compton DR, Sahoo B, Kerrigan SA, Burge MS, Nickels M, Green JL, Katzenellenbogen JA, Tchesnokov A, Hattersley G. Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Medicinal Chemistry Letters. February 2011, s. 124–9. doi:10.1021/ml1002508. PMID 24900290. 
  • Yin D, Xu H, He Y, Kirkovsky LI, Miller DD, Dalton JT. Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. The Journal of Pharmacology and Experimental Therapeutics. March 2003, s. 1323–33. doi:10.1124/jpet.102.040832. PMID 12604713. 
  • Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharmaceutical Research. February 2007, s. 328–35. doi:10.1007/s11095-006-9152-9. PMID 17063395. 
  • Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, Jones TK. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). Journal of Medicinal Chemistry. January 1999, s. 210–2. doi:10.1021/jm9806648. PMID 9925725. 
  • Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharmaceutical Research. August 2006, s. 1641–58. doi:10.1007/s11095-006-9024-3. PMID 16841196. 
  • VAN WAGONER, Ryan M.; EICHNER, Amy; BHASIN, Shalender; DEUSTER, Patricia A.; EICHNER, Daniel. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 28 November 2017, s. 2004. doi:10.1001/jama.2017.17069. 

fda.gov

ismni.org

  • Ke HZ, Wang XN, O'Malley J, Lefker B, Thompson DD. Selective androgen receptor modulators--prospects for emerging therapy in osteoporosis?. Journal of Musculoskeletal & Neuronal Interactions. 2005, s. 355. Dostupné online. PMID 16340136. 

nih.gov

ncbi.nlm.nih.gov

  • Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. Journal of Medicinal Chemistry. June 2009, s. 3597–617. doi:10.1021/jm900280m. PMID 19432422. 
  • Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT. Pharmacodynamics of selective androgen receptor modulators. The Journal of Pharmacology and Experimental Therapeutics. March 2003, s. 1334–40. doi:10.1124/jpet.102.040840. PMID 12604714. 
  • Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biological & Pharmaceutical Bulletin. November 2003, s. 1563–9. doi:10.1248/bpb.26.1563. PMID 14600402. 
  • Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology. January 2007, s. 4–12. doi:10.1210/en.2006-0843. PMID 17008401. 
  • Manfredi MC, Bi Y, Nirschl AA, Sutton JC, Seethala R, Golla R, Beehler BC, Sleph PG, Grover GJ, Ostrowski J, Hamann LG. Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators. Bioorganic & Medicinal Chemistry Letters. August 2007, s. 4487–90. doi:10.1016/j.bmcl.2007.06.007. PMID 17574413. 
  • Zhang X, Li X, Allan GF, Sbriscia T, Linton O, Lundeen SG, Sui Z. Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators. Journal of Medicinal Chemistry. August 2007, s. 3857–69. doi:10.1021/jm0613976. PMID 17636947. 
  • Long YO, Higuchi RI, Caferro TR, Lau TL, Wu M, Cummings ML, Martinborough EA, Marschke KB, Chang WY, López FJ, Karanewsky DS, Zhi L. Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity. Bioorganic & Medicinal Chemistry Letters. May 2008, s. 2967–71. doi:10.1016/j.bmcl.2008.03.062. PMID 18400499. 
  • Ke HZ, Wang XN, O'Malley J, Lefker B, Thompson DD. Selective androgen receptor modulators--prospects for emerging therapy in osteoporosis?. Journal of Musculoskeletal & Neuronal Interactions. 2005, s. 355. Dostupné online. PMID 16340136. 
  • Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. The Journal of Clinical Endocrinology and Metabolism. October 1999, s. 3459–62. doi:10.1210/jc.84.10.3459. PMID 10522980. 
  • Piu F, Gardell LR, Son T, Schlienger N, Lund BW, Schiffer HH, Vanover KE, Davis RE, Olsson R, Bradley SR. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. The Journal of Steroid Biochemistry and Molecular Biology. March 2008, s. 129–37. doi:10.1016/j.jsbmb.2007.11.001. PMID 18164613. 
  • Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. The Journal of Pharmacology and Experimental Therapeutics. February 2009, s. 663–70. doi:10.1124/jpet.108.146811. PMID 19017848. 
  • Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. January 2009, s. 385–95. doi:10.1210/en.2008-0674. PMID 18772237. 
  • Miller CP, Shomali M, Lyttle CR, O'Dea LS, Herendeen H, Gallacher K, Paquin D, Compton DR, Sahoo B, Kerrigan SA, Burge MS, Nickels M, Green JL, Katzenellenbogen JA, Tchesnokov A, Hattersley G. Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Medicinal Chemistry Letters. February 2011, s. 124–9. doi:10.1021/ml1002508. PMID 24900290. 
  • Yin D, Xu H, He Y, Kirkovsky LI, Miller DD, Dalton JT. Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. The Journal of Pharmacology and Experimental Therapeutics. March 2003, s. 1323–33. doi:10.1124/jpet.102.040832. PMID 12604713. 
  • Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharmaceutical Research. February 2007, s. 328–35. doi:10.1007/s11095-006-9152-9. PMID 17063395. 
  • Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, Jones TK. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). Journal of Medicinal Chemistry. January 1999, s. 210–2. doi:10.1021/jm9806648. PMID 9925725. 
  • Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharmaceutical Research. August 2006, s. 1641–58. doi:10.1007/s11095-006-9024-3. PMID 16841196. 

nytimes.com

priceplow.com

blog.priceplow.com

sbnation.com

web.archive.org

  • M.S. Steiner. Effect of GTx-024, a selective androgen receptor modulator (SARM), on stair climb and quality of life (QOL) in patients with cancer cachexia. J Clin Oncol. June 2010. Dostupné v archivu pořízeném dne 2012-08-25.  Archivovaná kopie. www.asco.org [online]. [cit. 2019-01-22]. Dostupné v archivu pořízeném z originálu dne 2012-08-25. 

wikimedia.org

commons.wikimedia.org

  • AETHYTA. English: Structure of RAD140.. [s.l.]: [s.n.], 2015-10-19. Dostupné online.